Your browser doesn't support javascript.
loading
Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer / 肿瘤防治研究
Cancer Research on Prevention and Treatment ; (12): 703-708, 2022.
Artigo em Chinês | WPRIM | ID: wpr-986571
ABSTRACT
As the first cyclin-dependent kinases 4 and 6 inhibitors, palbociclib significantly improved the survival of the patients with the hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer. Palbociclib is a crucial landmark in the development history of antineoplastic drugs. This article reviews the mechanism of palbociclib, and summarizes the clinical trials, side effects, and the application of palbociclib.

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Cancer Research on Prevention and Treatment Ano de publicação: 2022 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Cancer Research on Prevention and Treatment Ano de publicação: 2022 Tipo de documento: Artigo